IRLAB Therapeutics
ISIN: SE0012675361 | Ticker: IRLAB | LEI: 549300JAT34LHEI0DH60
Country: Sweden
Rooted in Nobel Prize-winning research, IRLAB has grown rapidly to become recognized and respected as a world-leader in understanding the complex neuropharmacology of CNS disorders and especially Parkinson’s disease. We have a well-defined, strategically focused R&D pipeline of powerful new treatments targeting the various stages of Parkinson’s as they worsen over time throughout the patient’s journey of neurodegeneration.
Having a full range of effective disease management options for Parkinson’s patients is regarded as essential by both the medical and patient communities – and at the same time potentially a blockbuster pharmaceutical business.
2013
HeadquartersArvid Wallgrens backe 20, 41346 Göteborg – Sweden
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 370,068,000.00 | 472,449,000.00 | 323,555,000.00 |
| Noncurrent Assets | N/A | 86,328,000.00 | 51,009,000.00 | 54,871,000.00 |
| Property Plant And Equipment | N/A | 4,317,000.00 | 8,348,000.00 | 8,009,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 82,011,000.00 | 42,661,000.00 | 46,862,000.00 |
| Current Assets | N/A | 283,741,000.00 | 421,440,000.00 | 268,684,000.00 |
| Trade And Other Current Receivables | N/A | 6,732,000.00 | 19,543,000.00 | 15,908,000.00 |
| Current Trade Receivables | N/A | 0.00 | 4,470,000.00 | 3,322,000.00 |
| Other Current Receivables | N/A | 4,711,000.00 | 6,274,000.00 | 6,367,000.00 |
| Current Tax Assets Current | N/A | N/A | 0.00 | 231,000.00 |
| Cash and cash equivalents | 110,527,000.00 | 277,009,000.00 | 401,897,000.00 | 252,776,000.00 |
| Equity And Liabilities | N/A | 370,068,000.00 | 472,449,000.00 | 323,555,000.00 |
| Equity | N/A | 347,880,000.00 | 399,481,000.00 | 290,831,000.00 |
| Issued Capital | N/A | 970,000.00 | 1,035,000.00 | 1,037,000.00 |
| Retained Earnings | N/A | -338,785,000.00 | -287,004,000.00 | -400,411,000.00 |
| Additional Paidin Capital | N/A | 685,630,000.00 | 685,450,000.00 | 690,205,000.00 |
| Noncurrent Liabilities | N/A | 1,270,000.00 | 3,566,000.00 | 381,000.00 |
| Current Liabilities | N/A | 20,918,000.00 | 69,402,000.00 | 32,343,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 3,683,000.00 | 12,302,000.00 | 10,031,000.00 |
| Current Accruals And Current Deferred Income Including Current Contract Liabilities | N/A | N/A | 48,420,000.00 | 13,435,000.00 |
| Other Current Liabilities | N/A | 3,773,000.00 | 5,645,000.00 | 5,282,000.00 |
| Line item in (sek) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 0.00 | 207,782,000.00 | 61,136,000.00 |
| Other Income | 404,000.00 | 124,000.00 | 141,000.00 |
| Employee Benefits Expense | 23,968,000.00 | 31,024,000.00 | 42,481,000.00 |
| Depreciation Amortisation And Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | 2,256,000.00 | 3,474,000.00 | 4,779,000.00 |
| Other Expense By Nature | 8,000.00 | 81,737,000.00 | 125,906,000.00 |
| Profit Loss From Operating Activities | -91,458,000.00 | 52,576,000.00 | -113,110,000.00 |
| Finance Income | 1,000.00 | 1,000.00 | 0.00 |
| Finance Costs | 196,000.00 | 796,000.00 | 297,000.00 |
| Profit Loss Before Tax | -91,653,000.00 | 51,781,000.00 | -113,406,000.00 |
| Income Tax Expense Continuing Operations | 0.00 | 0.00 | 0.00 |
| Profit (loss) | -91,653,000.00 | 51,781,000.00 | -113,406,000.00 |
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -91,653,000.00 | 51,781,000.00 | -113,406,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 196,000.00 | 796,000.00 | 297,000.00 |
| Interest Received Classified As Operating Activities | N/A | 1,000.00 | 0.00 | 0.00 |
| Cash Flows From Used In Operating Activities | N/A | -89,214,000.00 | 128,641,000.00 | -142,612,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 394,000.00 | 708,000.00 | 2,876,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | N/A | 0.00 | 500,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -394,000.00 | -708,000.00 | -3,376,000.00 |
| Proceeds From Issuing Shares | N/A | 275,495,000.00 | 0.00 | N/A |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 1,616,000.00 | 2,865,000.00 | 3,134,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 256,091,000.00 | -3,045,000.00 | -3,134,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | 166,482,000.00 | 124,888,000.00 | -149,121,000.00 |
| Cash and cash equivalents | 110,527,000.00 | 277,009,000.00 | 401,897,000.00 | 252,776,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 03.04.23 | Joakim Tedroff | Other | Buy | SEK 2,038,685.20 |
| 01.09.22 | Richard Godfrey | Other | Buy | SEK 174,457.00 |
| 30.08.22 | Viktor Siewertz | Other | Buy | SEK 1,420.00 |
| 29.08.22 | Viktor Siewertz | Other | Sell | SEK 1,408.00 |
| 15.07.22 | Joakim Tedroff | Other | Other | SEK 0.00 |
| 31.05.22 | Viktor Siewertz | Other | Buy | SEK 170,370.00 |
| 30.05.22 | Viktor Siewertz | Other | Buy | SEK 120,480.00 |
| 27.05.22 | Viktor Siewertz | Other | Buy | SEK 116,790.00 |
| 25.02.22 | Carola Elisabet Lemne | Other | Buy | SEK 329,500.00 |
| 25.02.22 | Carola Elisabet Lemne | Other | Sell | SEK 288,900.00 |
SE0012675361
LEI549300JAT34LHEI0DH60
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.